You are requesting a service from Dr. K to provide the listed item above to be shipped to the specified address on the order. Because this requires a prescription, you must have received an *Approval Message* from Dr. K to your Push Health account prior to requesting this service. You also must also pay your New Patient Fee if applicable. Do not request this service without prior approval or your request may be refunded minus a 5% processing fee. Returning clients may request a service when ready and do not need permission to request a new service. Please message us with any questions before you request a service and we will happy to assist you.
***AVAILABLE IN ALL OF OUR STATES***
INFO:
DOSING:
LDN (LOW DOSE NALTREXONE) INFO FROM STRIVE PHARMACY
AND SO MANY MORE CONDITIONS!
Medication Information
Low-Dose Naltrexone (LDN) provides a temporary blockade of opioid receptors resulting in a rebound effect, yielding an increase in endorphin production. This boost in endorphins promotes healing, regulates immunity, provides pain relief, and reduces inflammation. Therapeutic benefits of LDN are evident in autoimmune diseases, gastrointestinal disorders, chronic pain, mental health challenges, and inflammation.
Mechanism of Action
Low-Dose Naltrexone is simply a lower-than-standard dose of Naltrexone. Rather than its typical dosing of 50-100 mg for treating opioid-related issues, LDN is often prescribed in 0.5 - 4.5 mg doses. Sometimes it is even used in ultra-low-doses down to 0.1 mg for specific treatments. Unlike the normal function of Naltrexone in it's common dosing form, when used in a low-dose Naltrexone has a paradoxical effect in which it behaves differently when taken in low-dose compared to when taken in its standard dosage.
LDN can cause vivid dreams the first few weeks of therapy. Most common side effects include fatigue, insomnia, flu-like symptoms, decreased appetite, fatigue, anxiety, headache, or dizziness.
Do not use LDN treatment in patients who are receiving opioid analgesics, dependent on opioids, and those individuals who have failed the naloxone challenge test or who have a positive urine screen for opioids.

